The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
1-Isopropyl-3-[5-(1-phenethyl-piperidin-4-yl)-[1,3,4]oxadiazol-2-yl]-1H-indazole oxalate ID: ALA5286642
Max Phase: Preclinical
Molecular Formula: C27H31N5O5
Molecular Weight: 415.54
Associated Items:
Names and Identifiers Canonical SMILES: CC(C)n1nc(-c2nnc(C3CCN(CCc4ccccc4)CC3)o2)c2ccccc21.O=C(O)C(=O)O
Standard InChI: InChI=1S/C25H29N5O.C2H2O4/c1-18(2)30-22-11-7-6-10-21(22)23(28-30)25-27-26-24(31-25)20-13-16-29(17-14-20)15-12-19-8-4-3-5-9-19;3-1(4)2(5)6/h3-11,18,20H,12-17H2,1-2H3;(H,3,4)(H,5,6)
Standard InChI Key: STENMHAOBIBZMX-UHFFFAOYSA-N
Molfile:
RDKit 2D
37 40 0 0 0 0 0 0 0 0999 V2000
8.4330 -14.1855 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
7.7186 -14.5980 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.0041 -14.1855 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
7.7186 -15.4230 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.0041 -15.8355 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
8.4330 -15.8355 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
4.1235 -13.7333 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.8751 -14.0734 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.5404 -13.5930 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.4588 -12.7723 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.7060 -12.4346 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.0346 -12.9173 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.1277 -12.2907 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0450 -11.4706 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7140 -10.9890 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.4626 -11.3289 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.1311 -10.8480 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.0488 -10.0270 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.2922 -9.6892 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.6269 -10.1722 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2247 -16.3534 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2236 -17.1801 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.9377 -17.5925 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.9359 -15.9411 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6506 -16.3498 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6555 -17.1754 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4423 -17.4261 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.9237 -16.7552 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.4344 -16.0901 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7015 -18.2085 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1535 -18.8242 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5087 -18.3752 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6846 -15.3047 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4643 -15.0459 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.4595 -14.2217 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6741 -13.9716 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.1937 -14.6412 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
2 3 1 0
2 4 1 0
4 6 2 0
4 5 1 0
7 8 1 0
7 12 1 0
8 9 1 0
9 10 1 0
10 11 1 0
11 12 1 0
10 13 1 0
13 14 1 0
14 15 1 0
15 16 2 0
16 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
20 15 1 0
21 22 2 0
22 23 1 0
23 26 2 0
25 24 2 0
24 21 1 0
25 26 1 0
26 27 1 0
27 28 1 0
28 29 2 0
29 25 1 0
27 30 1 0
30 31 1 0
30 32 1 0
29 33 1 0
33 34 1 0
34 35 1 0
35 36 2 0
36 37 1 0
37 33 2 0
35 7 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 415.54Molecular Weight (Monoisotopic): 415.2372AlogP: 5.09#Rotatable Bonds: 6Polar Surface Area: 59.98Molecular Species: BASEHBA: 6HBD: ┄#RO5 Violations: 1HBA (Lipinski): 6HBD (Lipinski): ┄#RO5 Violations (Lipinski): 1CX Acidic pKa: ┄CX Basic pKa: 8.96CX LogP: 4.21CX LogD: 2.65Aromatic Rings: 4Heavy Atoms: 31QED Weighted: 0.44Np Likeness Score: -1.29
References 1. Nirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Ravella SR, Bogaraju N, Middekadi VR, Subramanian R, Palacharla RC, Benade V, Muddana N, Abraham R, Medapati RB, Thentu JB, Mekala VR, Petlu S, Lingavarapu BB, Yarra S, Kagita N, Goyal VK, Pandey SK, Jasti V.. (2021) Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease., 64 (15.0): [PMID:34251799 ] [10.1021/acs.jmedchem.1c00703 ]